Australia Markets open in 57 mins

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.42-0.07 (-1.28%)
At close: 04:00PM EDT
5.42 0.00 (0.00%)
After hours: 04:01PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.96
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 324.26
52-week low 35.09
50-day moving average 37.30
200-day moving average 311.12

Share statistics

Avg vol (3-month) 3644.9k
Avg vol (10-day) 31.4M
Shares outstanding 545.67M
Implied shares outstanding 6N/A
Float 827.39M
% held by insiders 12.07%
% held by institutions 1133.34%
Shares short (12 Jan 2023) 49.35M
Short ratio (12 Jan 2023) 416.18
Short % of float (12 Jan 2023) 425.48%
Short % of shares outstanding (12 Jan 2023) 420.47%
Shares short (prior month 14 Dec 2022) 49.31M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-14.77%
Return on equity (ttm)-24.68%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -74.03M
Net income avi to common (ttm)-72.33M
Diluted EPS (ttm)-1.11
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)258.86M
Total cash per share (mrq)5.67
Total debt (mrq)12.53M
Total debt/equity (mrq)4.80
Current ratio (mrq)22.75
Book value per share (mrq)7.16

Cash flow statement

Operating cash flow (ttm)-60.46M
Levered free cash flow (ttm)-41.02M